Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02612194 · FLOW

Participant flow

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer · Source last updated 2022-11-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    c-MET high (\> 50%), RON null (0-9%) Crizotinib: All arms will receive crizotinib.
    id
    FG000
    title
    Cohort 1
  2. description
    c-MET + (10-100%), RON + (10-100%) Crizotinib was administered orally at 250 mg twice daily.
    id
    FG001
    title
    Cohort 2
  3. description
    c-MET null (0-9%), RON + (10-100%) Crizotinib was administered orally at 250 mg twice daily.
    id
    FG002
    title
    Cohort 3
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        5
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        2
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      Early Study Termination
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        2
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        2
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    c-MET high (\> 50%), RON null (0-9%) Crizotinib: All arms will receive crizotinib.
    id
    FG000
    title
    Cohort 1
  2. description
    c-MET + (10-100%), RON + (10-100%) Crizotinib was administered orally at 250 mg twice daily.
    id
    FG001
    title
    Cohort 2
  3. description
    c-MET null (0-9%), RON + (10-100%) Crizotinib was administered orally at 250 mg twice daily.
    id
    FG002
    title
    Cohort 3
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        5
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        2
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      Early Study Termination
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        2
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        2
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice